Gelonghui, May 17丨British Healthcare (300677.SZ) announced that in order to further optimize the investment structure and enhance investment value, Inke Medical Technology Co., Ltd. (“English Healthcare” or the “Company”) plans to sign the “Anhui Hongtai Hecang Phase I Venture Capital Fund Partnership (Limited Partnership)” with Hefei Hongtai Shengda Venture Capital Co., Ltd. (hereinafter referred to as “Hefei Hongtai”) to participate in the investment of Anhui Hongtai Hecang Phase I Venture Capital Fund Partnership (Limited Partnership) with its own funds. Yes, the following (“Partnership” or “Fund” for short). The total amount of capital pledged by the partnership for the first delivery is RMB 2021 million (the currency is RMB, same below; the final scale is based on the actual amount raised), of which the company will pledge an investment of RMB 20 million as the limited partner (LP) of the partnership.
The fund's investment areas include life and health, medicine (especially innovative drugs and biotechnology) and related fields such as artificial intelligence, informatization, engineering technology (especially medical devices), etc., and the amount of investment in the upstream and downstream life and health industry chain must not be less than 70% of the investment amount of partnership enterprises.